ATOS - ATOSSA THERAPEUTICS, INC.

QQQ $ 613.28 $ -11.96 (-1.91 %)

DIA $ 485.45 $ -2.47 (-0.51 %)

SPY $ 681.35 $ -7.41 (-1.08 %)

TLT $ 87.29 $ -0.85 (-0.96 %)

GLD $ 395.38 $ 2.20 (0.56 %)

Previous Close

$ 0.825

Open

$ 0.90

Bid

$ 0.84 x 500

Ask

$ 0.84 x 300

Day's Range

$ 0.83 - $ 0.91

52 Week Range

$ 0.55 - $ 1.29

Volume

1,457,035

Average Volume

Market Cap

106.57M

Beta (5Y Monthly)

$ 1.86

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	11-12-2025	09-30-2025	10-Q
2	08-12-2025	06-30-2025	10-Q
3	05-13-2025	03-31-2025	10-Q
4	03-25-2025	12-31-2024	10-K
5	11-12-2024	09-30-2024	10-Q
6	08-12-2024	06-30-2024	10-Q
7	05-13-2024	03-31-2024	10-Q
8	04-01-2024	12-31-2023	10-K
9	11-13-2023	09-30-2023	10-Q
10	08-14-2023	06-30-2023	10-Q
11	05-15-2023	03-31-2023	10-Q
12	03-22-2023	12-31-2022	10-K
13	11-07-2022	09-30-2022	10-Q
14	08-08-2022	06-30-2022	10-Q
15	05-09-2022	03-31-2022	10-Q
16	02-28-2022	12-31-2021	10-K
17	11-15-2021	09-30-2021	10-Q
18	08-13-2021	06-30-2021	10-Q
19	05-14-2021	03-31-2021	10-Q
20	03-31-2021	12-31-2020	10-K
21	11-13-2020	09-30-2020	10-Q
22	08-13-2020	06-30-2020	10-Q
23	05-13-2020	03-31-2020	10-Q
24	03-26-2020	12-31-2019	10-K
25	11-13-2019	09-30-2019	10-Q
26	08-13-2019	06-30-2019	10-Q
27	05-13-2019	03-31-2019	10-Q
28	03-28-2019	12-31-2018	10-K
29	11-14-2018	09-30-2018	10-Q
30	08-13-2018	06-30-2018	10-Q
31	05-14-2018	03-31-2018	10-Q
32	03-08-2018	12-31-2017	10-K
33	11-13-2017	09-30-2017	10-Q
34	08-14-2017	06-30-2017	10-Q
35	05-11-2017	03-31-2017	10-Q
36	03-16-2017	12-31-2016	10-K
37	11-14-2016	09-30-2016	10-Q
38	08-12-2016	06-30-2016	10-Q
39	05-05-2016	03-31-2016	10-Q
40	03-30-2016	12-31-2015	10-K

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

why-are-shares-of-atossa-therapeutics-up-today

Why Are Shares Of Atossa Therapeutics Up T...
12/11/2025 17:26:50

Atossa Therapeutics, Inc. (NASDAQ: ATOS) stock is trading higher on Thursday. Here's what investors need to know.

Atossa Therapeutics Receives FDA Rare Pedi...
12/11/2025 13:11:59

Atossa Therapeutics Secures U.S. Patent fo...
12/09/2025 13:06:43

New patent further strengthens global intellectual property estate supporting Atossa's lead program across the breast cance...

Ascendiant Capital Maintains Buy on Atossa...
12/08/2025 10:35:06

Ascendiant Capital analyst Edward Woo maintains Atossa Therapeutics (NASDAQ:ATOS) with a Buy and raises the price target fro...

Atossa Therapeutics Completes Type C Meeti...
12/04/2025 13:07:23

Company positioned to pursue expedited regulatory pathways in metastatic, neoadjuvant, and risk-reduction settings

Insilico Medicine And Atossa Therapeutics ...
12/02/2025 13:20:41

Insilico Medicine ("Insilico"), a global leader in AI-powered drug discovery, and Atossa Therapeutics ("Atossa"...

Atossa Highlights (Z)-Endoxifen's Multi-Pa...
11/17/2025 14:11:28

Published article outlines rationale for multi-pathway efficacy for (Z)-endoxifen in Duchenne Muscular Dystrophy (DMD); Novembe...

Atossa Therapeutics Q3 EPS $(0.07), Inline
11/12/2025 13:18:14

Atossa Therapeutics (NASDAQ:ATOS) reported quarterly losses of $(0.07) per share which met the analyst consensus estimate. This...

Atossa Therapeutics To Present Four Abstra...
11/06/2025 13:31:40

Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical compan...

Atossa Highlights Enrollment Progress And ...
10/21/2025 12:17:57

Investor-focused update underscores enrollment momentum, biomarker strategy, and near-term data readouts designed to de-risk de...

Atossa Therapeutics Appoints Mark Daniel A...
10/14/2025 12:15:09

25+ year life-sciences finance leader brings revenue-forecasting rigor, public-company controls, and capital-markets experience...

Ascendiant Capital Maintains Buy on Atossa...
09/22/2025 09:28:37

Ascendiant Capital analyst Edward Woo maintains Atossa Therapeutics (NASDAQ:ATOS) with a Buy and raises the price target fro...

Atossa Therapeutics Announces It Has Reque...
09/08/2025 12:36:20

Atossa Therapeutics, Inc. (NASDAQ:ATOS, ", Atossa", or the ", Company", ))) announced today it has requested a ...

Atossa Therapeutics Selects PSI To Manage ...
08/20/2025 12:31:56

Monotherapy Phase 2 study designed with FDA input; IND expected in Q4 2025Topline results anticipated in 2026 Positions Atossa ...

Atossa Therapeutics Q2 EPS $(0.07) Misses ...
08/12/2025 12:38:44

Atossa Therapeutics (NASDAQ:ATOS) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of...

Atossa Therapeutics Announces FDA Feedback...
07/29/2025 11:46:15

Ascendiant Capital Maintains Buy on Atossa...
06/06/2025 10:40:29

Ascendiant Capital analyst Edward Woo maintains Atossa Therapeutics (NASDAQ:ATOS) with a Buy and raises the price target fro...

this-excelerate-energy-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-thursday

This Excelerate Energy Analyst Begins Cove...
06/05/2025 19:17:32

Craig-Hallum Initiates Coverage On Atossa ...
06/05/2025 17:15:59

Craig-Hallum analyst Albert Lowe initiates coverage on Atossa Therapeutics (NASDAQ:ATOS) with a Buy rating and announces Pri...

Atossa Therapeutics Reports Full Results F...
05/14/2025 12:19:03

Feasibility endpoint achieved; rapid Ki‑67 suppression and substantial MRI‑confirmed tumor shrinkage observed with favorable sa...